Q-omics provides the consensus-scored FURIN profile across patient tissues and cancer cell-line models. FURIN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FURIN is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, FURIN RNA expression shows 18,848 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where FURIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FURIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FURIN survival associations across molecular data types. FURIN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FURIN RNA expression–survival associations across cancer types. High FURIN expression shows unfavorable associations in CESC, LGG, LUAD and DLBC, but favorable associations in SCLC and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify CESC as the clearest survival context for FURIN RNA expression.
This table summarizes FURIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FURIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FURIN shows higher tumor expression in HNSC, LUAD, STAD, ESCA, BLCA and LUSC. The HNSC box plot shows higher FURIN RNA expression in tumor versus normal tissue (log2 FC = +1.335, t-test p < 0.001).
This table shows molecular features associated with FURIN in patient tissues and cancer cell lines. In patient samples, FURIN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FURIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
